Background

Gout is the most common inflammatory arthritis in developed countries.
- It is characterized by hyperuricemia or elevated serum uric acid levels.
- Most affected in men, and with a highest risk in African American males.
- Increased BSA and the presence of Ab were associated with an increased risk for hyperuricemia.
- The highest anti-pegloticase antibody observed for each individual was used as a covariate in the final PD model.
- Compliant response levels were used to model the PK/PD relationship.
- The highest anti-pegloticase antibody observed for each individual was used as a covariate in the final PD model.
- The highest anti-pegloticase antibody observed for each individual was used as a covariate in the final PD model.
- The highest anti-pegloticase antibody observed for each individual was used as a covariate in the final PD model.
- The highest anti-pegloticase antibody observed for each individual was used as a covariate in the final PD model.

Methods

- **PK Analysis:**
  - Generalized linear regression analysis was used to determine the effect of covariates on the PK of pegloticase.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
- **PD Analysis:**
  - The PD of pegloticase was characterized by a direct, inhibitory Emax model.
  - The PD model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
- **Population Pharmacokinetic and Pharmacodynamic Analysis:**
  - The final PK/PD model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - Incorporation of the PK/PD model into a PD model was done using the Akaike information criterion (AIC).
- **Antibody Response:**
  - Antibodies were non-neutralizing, and the inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.

Results

- **Population PK/PD Analysis:**
  - The PK/PD model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.

Discussion

- **PK/PD Model:**
  - The PD model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.

Conclusions

- **PK/PD Model:**
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.

- **Antibody Response:**
  - Antibodies were non-neutralizing, and the inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.

- **Population Pharmacokinetic and Pharmacodynamic Analysis:**
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.
  - The final model was chosen based on the Akaike information criterion (AIC) and the significance of the covariates.

- **Antibody Response:**
  - Antibodies were non-neutralizing, and the inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.
  - The inclusion of Ab as a significant covariate in the final PD model was consistent with the observed kinetic behavior.